# EU PATENT GRANTED - FURTHER EXTENDS XANAMEM PROTECTION

- **European Patent granted for use of Xanamem™ in Alzheimer's dementia and other diseases**
- **Comprehensive protection over Xanamem™ otherwise known as inhibitor to 11β-HSD1**
- **Xanamem™'s long patent life, now further extended to 2031**

**Sydney, 13 April 2015:** Actinogen Limited (Actinogen Medical, ASX: ACW), is pleased to announce it has received official notification to grant from the European Union Patent Office for patent application 11709770.9 entitled *3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)- [5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone and related compounds and their use*

This patent protects the use of Xanamem™ for use in Alzheimer's dementia and other related diseases associated with the inhibition of 11-beta-hydroxysteroid dehydrogenase (11β-HSD1). Importantly this European patent further extends the comprehensive cover to 2031.

This patent is in relation to pharmaceutical compositions of 11 β-HSD1 inhibitors and the use of these compounds to inhibit 11 β-HSD1 in order to treat disorders that are ameliorated by the inhibition of this enzyme. The claims in these patents cover method-to-treat for various diseases beyond Alzheimer's dementia including the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease. They also cover central nervous system (CNS) disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease, post-traumatic stress disorder, depression, schizophrenia etc.

Xanamem™ is a small molecule inhibitor of 11β-HSD1, an enzyme that reduces cortisone to the active hormone cortisol, which activates glucocorticoid receptors. There is significant evidence for the role of glucocorticoids and hypothalamus-pituitary–adrenal axis dysfunction in Alzheimer's dementia that includes both cortisol-induced neurotoxicity on the hippocampal formation and acute ongoing impairment of cognition.

Xanamem™ is currently being developed as a potential new therapy for Alzheimer's disease, a condition with a multi-billion dollar market potential. The cost of Alzheimer's treatment in the US alone was estimated to be US$250bn last year by the American Alzheimer's Association.

The drug works by blocking the development of cortisol - the stress hormone - in the hippocampus, the area of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.

Actinogen Medical is currently completing a second Phase I study on Xanamem™ with results expected mid-2015. It is set to start a Phase II Alzheimer's dementia study in early 2016 which is planned to run in Australia/New Zealand, Europe and the USA, under a US Food & Drug Administration (FDA) approved Investigational New Drug (IND).

**ENDS**

**Actinogen Medical**
Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
**@BillKetelbey**

**About Actinogen Medical**

Actinogen Medical is an Australian biotechnology company focused on the treatment of Alzheimer's disease and prodromal Alzheimers/Mild Cognitive Impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat Alzheimer's disease and other age-related neurodegenerative diseases. The lead candidate Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer's. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results expected in mid-2015. Actinogen Medical plans to initiate a Phase II study in Alzheimer's and prodromal Alzheimer's/Mild Cognitive Impairment in 2016.

**About Xanamem™**

Xanamem™ is under development as a potential new therapy for Alzheimer's disease and prodromal Alzheimers/Mild Cognitive Impairment, conditions with a multi- billion dollar market potential. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.